Popular Articles
Cellulite Treatment

Oxoid Provides Free Infection Control Seminar In The UK
Oxoid, a world leading microbiology brand, is pleased to announce that the next Oxoid Infection Control Seminar will take place on 02 June 2009 at The Belfry, West Midlands, UK. This all-day event is completely free of charge and is provided as an educational service to consultant microbiologists, laboratory managers/personnel and infection control professionals.
generic viagra online
Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold In Patients With Late-Stage Leukaemia
Clavis Pharma ASA (OSE: CLAVIS) announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned.
News of the day
Triathletes' Sperm Being Damaged By High Levels Of Cycling Training
The high-intensity training undertaken by triathletes has a significant impact on the quality of their sperm, the 25th annual conference of the European Society of Human Reproduction and Embryology heard 29 June. Professor Diana Vaamonde, from the University of Cordoba Medical School, Cordoba, Spain, said that the triathletes who did the most cycling training had the worst sperm morphology.
Public Health

MDS Nordion Opens New Radiopharmaceutical Production Facility In Belgium

MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced the opening of a facility in Fleurus, Belgium for the production of Fluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in positron emission tomography (PET) imaging. PET imaging produces a three-dimensional image, or picture, of functional processes in the body, such as brain activity, and is a highly accurate and effective method of diagnosing disease and managing patient therapy. MDS Nordion"s new facility will provide timely supply of F-18 FDG to hospitals throughout Belgium, France, The Netherlands, Luxembourg and Germany. "Customers count on MDS Nordion for leadership, quality products and customized services," said Steve West, President MDS Nordion. "Our investment in this facility further demonstrates our commitment to address the growing demand for PET diagnostic imaging in targeted European regions, and provides the medical community greater service for their future patient care." The PET imaging market is the most rapidly growing area of nuclear medicine and procedures. Statistics from a recent Medical Options survey indicates PET examinations are on a rapid rise in Europe, and are expected to grow at a compound annual rate of approximately 20% through 2012. To help meet increasing demand, this state-of-the-art, Good Manufacturing Practice (GMP) production facility will have three daily production runs and a customer service team available 24 hours a day, seven days a week. "PET imaging is effective because it allows early detection of tumours, as well as assessment of therapeutic strategies," said Professor Roland Hustinx, Nuclear Medicine Department, CHU - Universite de Liege. "In particular, MDS Nordion"s new facility will provide another of supply of F-18 FDG to existing and new medical facilities, thereby increasing the ability of health-care practitioners to conduct this critical type of imaging." MDS Nordion


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):